Last reviewed · How we verify
CD7 CAR-T cell intravenous infusion — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
CD7 CAR-T cell intravenous infusion (CD7 CAR-T cell intravenous infusion) — Institute of Hematology & Blood Diseases Hospital, China.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CD7 CAR-T cell intravenous infusion TARGET | CD7 CAR-T cell intravenous infusion | Institute of Hematology & Blood Diseases Hospital, China | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CD7 CAR-T cell intravenous infusion CI watch — RSS
- CD7 CAR-T cell intravenous infusion CI watch — Atom
- CD7 CAR-T cell intravenous infusion CI watch — JSON
- CD7 CAR-T cell intravenous infusion alone — RSS
Cite this brief
Drug Landscape (2026). CD7 CAR-T cell intravenous infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/cd7-car-t-cell-intravenous-infusion. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab